Literature DB >> 6831444

Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line.

R Giavazzi, E Scholar, I R Hart.   

Abstract

A variant cell line (UV-2237-ADMR) resistant to the anthracycline antibiotic Adriamycin (Doxorubicin) was selected in vitro from the murine UV-2237 fibrosarcoma tumor cell line. Resistance to Adriamycin proved to be a stable characteristic of the UV-2237-ADMR line, whether the line was grown in vivo or in vitro. The UV-2237-ADMR line also exhibited increased resistance to N-trifluoroacetyladriamycin-24-valerate, daunorubicin, actinomycin D, amsacrine, mitomycin C, vinblastine, and vincristine but not to bleomycin. Cell-cell hybridization studies showed that the Adriamycin resistance is an incompletely dominant trait. Uptake and efflux studies with [14C]Adriamycin indicated that the resistance exhibited by the UV-2237-ADMR line was due to both reduced uptake of the drug and an increased active efflux.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831444

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Macrophages and cancer.

Authors:  P W Whitworth; C C Pak; J Esgro; E S Kleinerman; I J Fidler
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

2.  Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Positive correlation between decreased cellular uptake, NADPH-glutathione reductase activity and adriamycin resistance in Ehrlich ascites tumor lines.

Authors:  M E Scheulen; H Hoensch; H Kappus; S Seeber; C G Schmidt
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

4.  Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.

Authors:  F Formelli; L Cleris; R Carsana
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines.

Authors:  C Etiévant; O Pauwels; R Kiss
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Expression of cell surface P-glycoprotein by an adriamycin-resistant murine fibrosarcoma.

Authors:  R Giavazzi; N Kartner; I R Hart
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells.

Authors:  W M Holleran; M W DeGregorio; R Ganapathi; J R Wilbur; B A Macher
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Antitumor activity of FCE 26644 a new growth-factor complexing molecule.

Authors:  F Sola; M Farao; E Pesenti; A Marsiglio; N Mongelli; M Grandi
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  In vivo characterization of a doxorubicin resistant B16 melanoma cell line.

Authors:  F Formelli; C Rossi; R Supino; G Parmiani
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

10.  The in vitro effects and cross-resistance patterns of some novel anthracyclines.

Authors:  P R Twentyman; N E Fox; K A Wright; P Workman; M J Broadhurst; J A Martin; N M Bleehen
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.